Abbott Laboratories

NYSE:ABT   11:32:25 AM EDT
118.49
+1.04 (+0.88%)
Products

Abbott's BinaxNOW Covid-19 Rapid Test Receives FDA Emergency Use Authorization

Published: 12/16/2020 19:01 GMT
Abbott Laboratories (ABT) - Abbott's Binaxnow Covid-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-home Rapid Test Using Emed's Digital Health Platform.
Abbott Laboratories - Co & Emed Expect to Deliver and Administer 30 Million Binaxnow Tests in Q1 of 2021, With an Additional 90 Million in Q2.
Abbott Laboratories - Emed Service Offering Costs $25 a Test.